Skip to main content
Vaishali Pharma Limited logo

Vaishali Pharma Limited — Investor Relations & Filings

Ticker · VAISHALI ISIN · INE972X01022 LEI · 335800LHHVE3JLLKP681 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 428 across all filing types
Latest filing 2024-06-07 Capital/Financing Update
Country IN India
Listing National Stock Exchange of India VAISHALI

About Vaishali Pharma Limited

https://www.vaishalipharma.com/

Vaishali Pharma Limited specializes in the sourcing, marketing, and distribution of a comprehensive range of healthcare products. The company’s portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations in various dosage forms such as tablets and injectables, and surgical supplies. It also provides veterinary products, herbal supplements, and nutraceuticals. The business model focuses on integrated supply chain management, facilitating the movement of medical products from manufacturing units to global markets. By adhering to international quality standards and leveraging an extensive distribution network, the company serves diverse therapeutic requirements. Its operations emphasize reliability in procurement and the delivery of cost-effective healthcare solutions to a global clientele across multiple regions, including Africa, Asia, and Latin America.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to the National Stock Exchange of India Limited regarding the outcome of a Board Meeting held on June 7, 2024. The content details the approval and allotment of equity shares upon conversion of warrants, including specifics about the number of shares allotted, the increase in paid-up capital, and the names of the allottees. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes a disclosure annexure related to the conversion of warrants and allotment of equity shares. This is a clear update on the company's capital structure and financing activities, specifically about share allotment following warrant conversion. It is not a full financial report, audit, or earnings release, nor is it a meeting presentation or voting result. It is a capital/financing update as it informs about changes in share capital due to warrant conversion and allotment. The document length (4533 characters) and detailed content support classification as a Capital/Financing Update rather than a brief announcement or regulatory filing.
2024-06-07 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding the publication in newspapers of the audited financial results for the quarter and year ended March 31, 2024. It references Regulation 47 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and states that copies of the newspaper publication of the audited financial results are enclosed. The document does not contain the financial results themselves but is an announcement that the audited financial results have been published in newspapers. The document length is 15,000 characters, but the content is primarily an announcement of publication rather than the report itself. According to the "Menu vs Meal" rule, this is a report publication announcement rather than the actual financial report. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2024-05-31 English
Financial Result Updates
Regulatory Filings
2024-05-30 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notice from Vaishali Pharma Limited to the National Stock Exchange of India about an upcoming Board Meeting scheduled for May 30, 2024. The notice mentions the agenda items including approval of audited annual financial results for the year ended March 31, 2024, and related financial statements. It is a formal intimation of a board meeting rather than the meeting materials or the financial results themselves. The document is short (2016 characters) and serves as an announcement of the meeting, not the report or results. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2024-05-23 English
Board Meeting — VAISHALI PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the…
Regulatory Filings
2024-05-23 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notice from the company to the stock exchange about an upcoming Board Meeting scheduled for May 30, 2024. It mentions the agenda items including approval of audited annual financial results and related statements for the year ended March 31, 2024. The document is short (2020 characters) and serves as an intimation or announcement of the meeting rather than containing the actual financial results or reports. It also references regulatory compliance regarding insider trading and trading window closure. This fits the category of a Board/Management Information filing, as it announces a board meeting and related corporate governance matters, but does not contain the full report or financial data itself.
2024-05-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.